HiFiBiO Therapeutics

HiFiBiO Therapeutics is a clinical-stage biotech driving a pipeline of transformative immunotherapies. The company targets the root cause of disease through its Drug Intelligence Science (DIS®) platform, which uses proprietary single-cell technology and AI/ML analytics to understand cellular pathology and is deployed in target discovery, antibody selection, and predictive biomarker identification. It started in 2017 with the goal of leveraging deep immune modulation expertise and single-cell technology to deliver transformative medicines to patients.

HiFiBiO Therapeutics started in 2017 with the goal of leveraging deep immune modulation expertise and cutting edge single cell technology to deliver transformative medicines to patients. The company is a clinical-stage biotech driving a pipeline of transformative immunotherapies, targeting the root cause of disease through its Drug Intelligence Science (DIS®) platform. Fred Dom is one of the original founders and Chief Executive Officer; he previously held CEO and CFO positions at HiFiBiO Therapeutics.

Clinical-stage biotech pioneering curative immunotherapies for patients with high unmet medical needs.

• EMUNKITUG (HFB200301)

• HFB200603

• NUVUSTOTUG (HFB301001)

• HFB200604

• HFB3024

1. 1Home - HiFiBiO Therapeuticshifibio.com
2. 2Company Overview - HiFiBio Therapeuticshifibio.com
3. 3Contact - HiFiBio Therapeuticshifibio.com
4. 4Leadership - HiFiBio Therapeuticshifibio.com
5. 5HiFiBiO Therapeutics (France)wikidata.org